Interaction Guide · Research summary

Can I take Fish Oil with Prasugrel?

Review Fish Oil with Prasugrel: timing and monitoring, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

A blanket fish-oil avoidance or spacing rule with prasugrel is not established. Review the exact EPA/DHA product and procedure plans with your treating team.

What this answer covers

Oral fish oil containing EPA and DHA with oral prasugrel hydrochloride tablets. Purified EPA prescriptions, ALA and all omega-3 doses are not interchangeable.

Supplement or preparation
Fish Oil
Medication ingredient
prasugrel

A large trial provides useful counterevidence

The OPERA bleeding analysis included 1,516 cardiac-surgery patients given EPA plus DHA fish oil or placebo. Major perioperative bleeding was not increased with that regimen. This challenges a blanket assumption that all fish oil necessarily increases bleeding, but does not resolve this exact drug combination.

Read the EPA and DHA amounts

Record the daily EPA and DHA dose and whether this is a prescription product or supplement. The trial used a particular preoperative loading and maintenance regimen. It cannot be extended to every omega-3 formulation, purified EPA or unlimited doses.

Plan procedures with your treating team

Prasugrel is an antiplatelet medicine supplied in hydrochloride tablets. It can cause serious bleeding, but stopping it prematurely after stent treatment can also cause serious harm. Its platelet effect lasts longer than the active metabolite remains in blood, so a short gap between doses is not an established way to prevent supplement-related bleeding. Tell the team about fish oil before a procedure; do not create your own stopping or spacing schedule.

Know when to get help

Seek urgent care for bleeding that will not stop, vomiting blood or black, tarry stools. Tell your prescriber about the full supplement and medicine list. Do not stop prescribed antiplatelet treatment on your own to accommodate a supplement; ask the treating team to make a plan.

Evidence and practical considerations

Timing & monitoring

A routine fish-oil avoidance rule or protective spacing interval with prasugrel is not established.

Exact scope
Oral fish oil containing EPA and DHA with oral prasugrel hydrochloride tablets. Purified EPA prescriptions, ALA and all omega-3 doses are not interchangeable. with Exact prasugrel RxCUI613391 IN. Current label identifies racemic hydrochloride tablets expressing5/10mg prasugrel-equivalent doses; active metabolite exposure is distinguished from parent ingredient.
Medication form and route
Oral

What remains uncertain

  • Large surgical trial tested a defined EPA/DHA regimen, not an exact prasugrel- or ticagrelor-specific interaction. Results do not establish safety for every formulation or high-dose purified EPA.

Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.

Research conclusion: insufficient evidence · Evidence assessment: low

Read the supporting source summaries

Source 1: Current prescribing information

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Prescription oral oral prasugrel hydrochloride tablets users; short human pharmacology studies where described.

Serious bleeding risk; premature discontinuation may increase stent thrombosis, MI or death. Rifampin did not change active-metabolite exposure; label expects no important CYP-induction effect.

How this applies: Exact current product label. Exact prasugrel RxCUI613391 IN. Current label identifies racemic hydrochloride tablets expressing5/10mg prasugrel-equivalent doses; active metabolite exposure is distinguished from parent ingredient.

Exact salt-to-IN bridge from product label; no herb-specific bleeding rate. Original rifampin study retained modest platelet differences beyond simplified label summary.

Source 2: Original clinical research

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: 1516 cardiac-surgery patients in the randomized OPERA trial bleeding analysis.

Major perioperative bleeding was not increased versus placebo; odds ratio 0.81, 95% CI 0.53-1.24. Fewer transfusion units were used.

How this applies: Indirect for oral prasugrel hydrochloride tablets co-use; exact preparation and endpoint retained.

Abstract-only for this capture. Not a trial of chronic oral prasugrel hydrochloride tablets co-use. Cardiac surgery is a different setting; the exact antiplatelet co-use was not the randomized exposure. Does not represent purified EPA, ALA or all doses.

Source 3: Medication terminology

rxnav.nlm.nih.gov · Source check Sep 10, 2026

Population: Terminology.

prasugrel is IN.

How this applies: Exact identity.

Not clinical evidence.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Article prepared
Sources checked and article drafted.
Research summary published

Article revision: d49deaba16b1e79e

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.